Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells
ConclusionPI3K inhibitors such as PI-103, PI-828 and PX-866 may be developed as potential therapeutic agents for effective treatment of oral squamous cell carcinoma (OSCC) patients, associated with activated PI3K/Akt pathway.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Translocation